These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 25867257)

  • 1. Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients.
    Mizuno M; Kajiyama H; Shibata K; Mizuno K; Kawai M; Nagasaka T; Kikkawa F
    Br J Cancer; 2015 Apr; 112(8):1376-83. PubMed ID: 25867257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian Carcinoma: A Single-Centre Eight-Year Case-Series Study with Survival Analysis.
    Subtirelu GD; Steriu A; Bratucu E
    Chirurgia (Bucur); 2024 Aug; 119(4):373-384. PubMed ID: 39250607
    [No Abstract]   [Full Text] [Related]  

  • 6. The survival benefit associated with complete macroscopic resection in epithelial ovarian cancer is histotype specific.
    Porter JM; McFarlane I; Bartos C; Churchman M; May J; Herrington CS; Connolly KC; Ryan NAJ; Hollis RL
    JNCI Cancer Spectr; 2024 Jul; 8(4):. PubMed ID: 38902938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
    Colombo PE; Labaki M; Fabbro M; Bertrand M; Mourregot A; Gutowski M; Saint-Aubert B; Quenet F; Rouanet P; Mollevi C
    Gynecol Oncol; 2014 Nov; 135(2):223-30. PubMed ID: 25220627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary epithelial ovarian carcinoma in Taiwanese women.
    Wang PH; Yuan CC; Juang CM; Lai CR; Yen MS; Chao HT; Ng HT
    Eur J Gynaecol Oncol; 2001; 22(1):57-60. PubMed ID: 11321496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
    Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
    Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
    Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
    Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up.
    Geisler JP; Tammela JE; Manahan KJ; Geisler HE; Miller GA; Zhou Z; Wiemann MC
    Eur J Gynaecol Oncol; 2004; 25(2):165-8. PubMed ID: 15032273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten years' experience with centralized surgery of ovarian cancer in one health region in Norway.
    Aune G; Torp SH; Syversen U; Hagen B; Tingulstad S
    Int J Gynecol Cancer; 2012 Feb; 22(2):226-31. PubMed ID: 22080889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer?
    Lydiksen L; Jensen-Fangel S; Blaakaer J
    Gynecol Oncol; 2014 Jun; 133(3):454-9. PubMed ID: 24726613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
    Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
    Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: Results from a single-center Taiwanese study.
    Ku FC; Wu RC; Yang LY; Tang YH; Chang WY; Yang JE; Wang CC; Jung SM; Lin CT; Chang TC; Chao A; Lai CH
    J Formos Med Assoc; 2018 Feb; 117(2):117-125. PubMed ID: 28389144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic analysis of ovarian cancer associated with endometriosis.
    Kumar S; Munkarah A; Arabi H; Bandyopadhyay S; Semaan A; Hayek K; Garg G; Morris R; Ali-Fehmi R
    Am J Obstet Gynecol; 2011 Jan; 204(1):63.e1-7. PubMed ID: 21074136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
    Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term prognosis of stage I ovarian carcinoma. Prognostic importance of intraoperative rupture.
    Mizuno M; Kikkawa F; Shibata K; Kajiyama H; Suzuki T; Ino K; Kawai M; Mizutani S
    Oncology; 2003; 65(1):29-36. PubMed ID: 12837980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.